Mesoblast Ltd represents values of innovation, integrity, and collaboration in the field of regenerative medicine. The company aims to develop and commercialize cell-based therapies that have the potential to improve patients' lives. With a focus on advanced manufacturing and rigorous clinical trials, Mesoblast is committed to delivering safe and effective treatments for a variety of conditions, including cardiovascular diseases, orthopedic disorders, and immune-mediated inflammatory diseases. By collaborating with leading research institutions and pharmaceutical partners, Mesoblast strives to be at the forefront of scientific advancements and bring innovative therapies to the market.

Mesoblast Ltd is primarily present in multiple countries and regions worldwide. The company's global presence extends to various key markets, including the United States, Japan, Australia, and Europe. With a robust international footprint, Mesoblast Ltd has established itself as a leading biopharmaceutical company, dedicated to innovative cellular medicines.

Mesoblast Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 3 pivotal trial for its flagship product, remestemcel-L, in the treatment of graft-versus-host disease (GVHD). Mesoblast also received fast track designation from the U.S. FDA for this potential groundbreaking therapy. Additionally, the company forged strategic partnerships with major pharmaceutical companies, including JCR Pharmaceuticals and Grünenthal, to expand its product pipeline and accelerate commercialization efforts. Mesoblast's groundbreaking research and development efforts, along with its partnerships and successful clinical trials, demonstrate its commitment to revolutionizing the treatment of various diseases and solidify its position as an innovative leader in the healthcare industry.

Mesoblast Ltd is a renowned biopharmaceutical company specializing in the development of innovative cellular medicines. Founded in 2004, Mesoblast has excelled in the field of regenerative medicine, aiming to provide effective treatments for challenging inflammatory ailments. With a focus on harnessing the unique regenerative properties of cells, Mesoblast has successfully developed a diverse pipeline of potential therapies. The company has made significant strides in areas such as cardiovascular conditions, orthopedic disorders, and immune-mediated diseases. Mesoblast's dedication to innovation and scientific excellence has positioned it as a global leader in the field of cellular medicines.

Some of the main competitors of Mesoblast Ltd in the market are Novartis AG, Johnson & Johnson, Pfizer Inc., and Athersys Inc.

Mesoblast Ltd is primarily active in the biotechnology and regenerative medicine industries.

The business model of Mesoblast Ltd revolves around developing and commercializing innovative cellular medicines. As a leading global biopharmaceutical company, Mesoblast focuses on leveraging its proprietary allogeneic cell therapy platform to address significant unmet medical needs. By harnessing the power of mesenchymal lineage adult stem cells, Mesoblast aims to deliver effective treatments across a broad range of inflammatory and immune-mediated diseases, cardiovascular conditions, and orthopedic disorders. This commitment to pioneering research and development, coupled with strategic collaborations and a strong intellectual property portfolio, enables Mesoblast to transform the lives of patients worldwide through the potential of regenerative medicine.

Mesoblast P/E suhe on −1,08.

Mesoblast KUV on 75,26.

AlleAktien kvaliteediskoor ettevõttele Mesoblast on 1/10.

oodatud Mesoblast käive on 6,46 mln. USD.

oodatud Mesoblast kasum on −451,55 mln. USD.

Mesoblast Ltd is an Australian biotechnology company specializing in the development of cellular and regenerative therapies. The company's business model focuses on utilizing its proprietary Mesenchymal Stem Cell technology platform to develop novel therapies for serious medical conditions. The company has three main divisions: Cardiovascular Diseases, Inflammatory Diseases, and Oncology, each responsible for the development of specific treatments. Mesoblast works closely with the academic community and the biopharmaceutical industry to validate its technology platform and bring its products to market. Mesoblast's product range includes Mesenchymal Stem Cell therapies for various indications. Currently, Mesoblast's product portfolio is still in clinical development, but the company has already achieved some important milestones. The Cardiovascular Diseases division is responsible for the development of mesenchymal stem cell therapies for the treatment of cardiovascular diseases. The company has already completed a Phase 3 clinical trial for its heart failure therapy, which has shown promising results. Additionally, Mesoblast's Chronic Heart Failure therapy is currently in clinical trials. The Inflammatory Diseases division includes anti-inflammatory stem cell therapies for the treatment of inflammatory diseases such as rheumatoid arthritis and graft-versus-host disease (GvHD). Mesoblast's GvHD therapy has already received approval from the US Food and Drug Administration and is currently available on the market. The Oncology division is responsible for the development of mesenchymal stem cell therapies for the treatment of cancer. Mesoblast's technology platform allows for targeting a wide range of cancer cells, and the company has already achieved positive results in a Phase 2 clinical trial with a cancer therapy. Another important area of business for Mesoblast is partnerships with other pharmaceutical and biotechnology companies. Mesoblast recently signed an agreement with Novartis to distribute its Hematopoietic Stem Cell Transplantation treatment in the EU region. Additionally, the company is working closely with Tasly Pharmaceuticals to develop a product upgrade for Tasly's prostate cancer medication. Mesoblast's cellular stem cell technology platform forms the foundation for its products and is a significant competitive advantage. Mesenchymal stem cells have the ability to differentiate into various types of cells such as bone, cartilage, adipose tissue, and muscle. Overall, Mesoblast is a company dedicated to the development of innovative cellular and regenerative therapies that have the potential to improve the lives of patients with serious diseases. The company has already achieved important milestones and is working towards bringing its therapies to market, enabling further growth for the company.

Mesoblast maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Mesoblast jaoks arvutada või ettevõte ei maksa dividende välja.

Mesoblast ISIN on AU000000MSB8.

Mesoblast WKN on A0DNPW.

Mesoblast tähis on MSB.AX.

Viimase 12 kuu jooksul maksis Mesoblast dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Mesoblast tõenäoliselt dividendi summas 0 USD.

Mesoblast praegune dividenditootlus on .

Mesoblast maksab kvartaalset dividendi. See makstakse välja kuudel .

Mesoblast maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Mesoblast on liigitatud sektorisse 'Tervis'.

Viimase Mesoblast dividendide saamiseks 13.9.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 13.9.2024.

Viimane dividendimakse toimus 13.9.2024.

Aastal 2023 maksis Mesoblast 0 USD dividende.

Mesoblast dividendid makstakse välja USD.